TENS (Transcutaneous Electrical Nerve Stimulation) — Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy describes medical necessity criteria, coverage, and reimbursement for TENS devices and supplies for Blue Cross Blue Shield of North Carolina members, including initial trial, continuation, and investigational indications.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial therapeutic trial (Covered)
Covered when ALL of the following are met:
As stated in policy: a 30-day monitored trial may be considered medically necessary.
Refractory chronic pain defined as failure of ≥3 months conservative therapy.
Documentation requirements described in Policy Guidelines (see required documentation list).
Continued use (Covered)
Covered when ALL of the following are met:
Objective improvement threshold referenced in Policy Guidelines.
Compliance must be monitored and documented by the physician.
Ongoing monitoring and documentation by the physician every 3 months is required for continued use beyond 12 months.
Investigational / Not covered indications
Not covered or considered investigational in the following situations:
Policy explicitly lists acute pain <3 months as investigational.
Policy presents mixed evidence for migraine; When Not Covered updates list prevention/treatment of migraines as investigational.
Policy enumerates multiple specific investigational indications.
Initial therapeutic trial requirements
Covered when ALL of the following are met
Definition and duration requirements appear in Policy Guidelines and Implementation history.
Compliance should be demonstrated with device use on a regular (daily or near-daily) basis during the trial.
These documentation elements are specified in Policy Guidelines to determine efficacy and medical necessity.
Transcutaneous electrical nerve stimulation (TENS) is considered investigational for the management of acute pain (less than 3 months) — for example, acute postoperative pain or pain during labor and delivery — and for numerous other listed conditions. The policy specifically lists acute and chronic headaches, prevention and treatment of migraines, temporomandibular joint dysfunction (TMJ), dementia, chest pain, fibromyalgia, pain in burns, chemotherapy‑induced neuropathy, amputation (phantom) pain, pelvic pain, post‑joint replacement pain, ADHD, and tremor as investigational indications. In addition, transcutaneous electrical modulation pain reprocessing (Scrambler therapy with the Calmare® device) is considered investigational for all indications.
The policy states that TENS is not recommended for management of acute pain such as postoperative pain or pain during labor and delivery and clarifies that TENS for the prevention and treatment of migraines is considered investigational. Historically, the policy’s "When Not Covered" updates have added other non‑covered items (for example, ADHD and tremor were added in 3/31/21 updates) and the billing/coding section has been revised repeatedly to reflect coding changes; these implementation notes are recorded in the policy history.
TENS is considered not medically necessary for management of refractory chronic pain when the policy’s required criteria are not met. To be covered for refractory chronic pain, members must meet the policy’s conditions including prior failure of at least 3 months of conservative therapy, a physician‑monitored initial therapeutic trial, demonstration of efficacy during that trial (for example, an objective improvement such as a ≥2‑point or 30% reduction on a visual analog scale), and documentation of near‑daily device use as required by the policy. Failure to provide the required documentation or to meet the therapeutic trial and prior conservative therapy requirements will result in denial as not medically necessary.
The policy previously included the statement that "Chronic pain management with the use of Axon Therapy is considered investigational." That language and related Axon Therapy references were subsequently removed from the policy (noted in the 5/6/26 update). The historical entry is retained here for context only to document the prior position and the date of its removal; it does not represent current policy language regarding Axon Therapy.
Billing, Codes, and Frequency Limits
| A4541 | |
| A4542 | |
| A4557 | Replacement lead wires (not usually more than once per 12 months) |
| A4595 | TENS supplies (reimbursed limited to one unit per month for 2‑lead, two units for 4‑lead) |
| A4630 | Batteries |
| E0720 | Transcutaneous electrical nerve stimulator, two lead, localized stimulation |
| E0730 | Transcutaneous electrical nerve stimulator, four lead, general use |
| E0731 | |
| E0733 | |
| E0734 |
| E1399 | Miscellaneous DME (likely used for Cefaly device) |
| K1016 | HCPCS code (listed in 2021 additions) |
| K1017 | HCPCS code (listed in 2021 additions) |
| K1018 | HCPCS code (listed in 2021 additions) |
| K1019 | HCPCS code (listed in 2021 additions) |
| K1023 | HCPCS code (added 11/2/21) |
| 0766T | CPT code (added effective 1/1/2023) |
| 0767T | CPT code (added effective 1/1/2023) |
| 0768T | CPT code (previously added; later removed) |
| 0769T | CPT code (previously added; later removed) |
| A4540 | CPT/HCPCS code (added effective 1/1/2024) |
Provider Responsibilities, Documentation, and Billing Guidance
Prior authorization / coding: medical necessity and records may be requested
Coverage and reimbursement for TENS devices and supplies are subject to the policy medical necessity criteria; BCBSNC may request medical records to determine necessity and may require documentation to support physician monitoring of the trial.
- Inclusion of codes in the Billing/Coding section does not guarantee reimbursement; see administrative policies for details.
- BCBSNC may request medical records when determining medical necessity.
Billing/coding updates: codes added and removed over time
The Billing/Coding section of the policy has been updated repeatedly; specific HCPCS and CPT codes have been added and removed over time, so providers should verify current billable codes before submission.
- Policy history documents additions and removals of codes (e.g., K1016–K1019 added 4/1/2021, later removed; A4540–A4542 and others added effective 1/1/2024).
- Inclusion of a code in the section does not guarantee reimbursement.
Conservative therapy required before TENS: ≥3 months
A trial of conservative medical therapy of at least 3 months is required before initiating a TENS therapeutic trial for refractory chronic pain.
- Conservative therapy may include physical therapy, medications, bracing, and other interventional treatments.
- Policy defines refractory chronic pain as pain not responding to at least 3 months of conservative therapy.
Continued use: demonstrate efficacy and compliance
Continued use beyond the initial trial may require documentation demonstrating efficacy during the initial therapeutic trial and evidence of compliance with near-daily device use during that trial.
- Efficacy must be demonstrated in the initial therapeutic trial (see policy guidelines for objective measures).
- For continued use beyond 12 months, physician documentation of near daily use every three months is required.
Required documentation for trial: assessment, prior treatments, and 1‑month clinical summary
Documentation for the trial period must include the initial assessment, prior treatments and durations, the treatment plan with proposed TENS use, and a clinical summary after at least 1 month documenting objective improvement, medication use, functional status, and actual device use.
- Initial assessment: nature, duration, and perceived intensity of pain.
- Prior treatments: types and duration (medication, bracing, physical therapy, etc.).
- Treatment plan: ongoing medications and proposed frequency/duration of TENS use.
- Clinical summary after ≥1 month: ≥2-point or 30% improvement on VAS (or similar), changes in medication use, functional improvement, and daily device use to assess compliance.
Medical records and coding note: records may be requested; letters alone may be insufficient
BCBSNC may request medical records to determine medical necessity; letters of support alone are not sufficient unless they include all specific information required for the medical necessity determination.
- When medical records are requested, letters of support/explanation are useful but insufficient unless they contain all necessary clinical details.
- Codes applicable to billing are listed in the policy but inclusion does not guarantee reimbursement.
Definition of refractory chronic pain: ≥3 months failed conservative therapy
Refractory chronic pain is defined as pain that causes significant disruption of function and has not responded to at least 3 months of conservative therapy; this definition guides eligibility for a TENS therapeutic trial.
- Conservative therapy examples include NSAIDs, rest, physical therapy, medications, bracing, and other interventional treatments.
- A monitored 30-day therapeutic trial may be appropriate to establish efficacy for patients meeting this definition.
Denial risk: unmet coverage criteria will lead to noncoverage
Failure to meet the policy coverage criteria—such as not having a documented ≥3‑month conservative therapy trial, lack of physician-monitored initial trial, or no demonstrated efficacy—will result in TENS being considered not medically necessary and denied.
- Denial risk applies when initial trial, demonstration of efficacy, or required documentation are not met.
- TENS for acute pain (<3 months) and other investigational indications are not covered.
Not covered example: TENS for migraine prevention is investigational
TENS for prevention of migraine headaches is considered investigational and not covered per the policy 'When Not Covered' updates.
- Policy implementation notes (11/11/14) added that TENS for prevention of migraine headaches is investigational.
- The 'When Not Covered' section lists prevention and treatment of migraines among investigational indications.
Required Prior Conservative Treatments
Supply and Replacement Frequency Limits
Imaging and Diagnostic Requirements
Imaging — none specified in policy
The policy does not specify any imaging requirements for TENS; no imaging studies are required by the policy.
- Policy imaging requirements section states 'No imaging requirements specified.'
Background and Technology Summary
Transcutaneous Electrical Nerve Stimulation (TENS) is a noninvasive neuromodulation technique that delivers electrical stimulation through surface electrodes to modulate pain signaling. Devices are available for home use and some related transcutaneous neurostimulation devices have specific regulatory clearances. The policy frames TENS primarily as a treatment option for chronic, refractory pain when specified conservative therapies have failed and when an initial monitored therapeutic trial demonstrates benefit; evidence quality and indications vary by condition, and several indications remain investigational.
Key Definitions
Not Covered / Investigational Indications
The policy’s explicit not covered list includes acute pain of less than 3 months (for example, acute postoperative pain and pain during labor and delivery) and enumerates a number of other investigational indications. Those additional investigational or not‑covered conditions include prevention and treatment of migraines, temporomandibular joint dysfunction, dementia, chest pain, fibromyalgia, burn pain, chemotherapy‑induced neuropathy, phantom limb pain, pelvic pain, post‑joint replacement pain, ADHD, tremor, and Scrambler (Calmare) therapy (the latter considered investigational for all indications). Policy implementation notes document additions and clarifications to this not‑covered list across multiple updates.
Policy History and Updates
Original policy established noting generally accepted medical practice for acute postoperative pain and chronic intractable pain.
Policy reaffirmed.
Policy reaffirmed.
Reviewed and deemed eligible for coverage for acute postoperative pain and chronic intractable pain; use for labor and vaginal delivery considered investigational.
Policy reaffirmed; National Association reviewed 11/30/96.
Policy reaffirmed by Medical Policy Advisory Group and HCPCS codes E0720 and E0730 were added.
Policy reformatted and medical term definitions added.
Specialty Matched Consultant Advisory Panel reviewed (two panels); no change recommended to criteria following Medical Policy Advisory Group review.
Added statement under noncovered indications that sequential stimulators were considered 'deluxe' models and not covered; A4595 and E0731 added to coding.
Policy name changed to TENS (Transcutaneous Electrical Nerve Stimulator).
Policy revised to include sympathetic therapy as investigational under when it is not covered; format changes made.
Specialty Matched Consultant Advisory Panel review on 7/12/2002 with no changes.
System coding changes implemented.
Added statement directing readers to Interferential Stimulation policy; no changes to coverage criteria.
Removed statement about sequential stimulators as deluxe models and added reference to Interferential Stimulator policy; Billing/Coding section updated for consistency.
Specialty Matched Consultant Advisory Panel review (6/22/2004); removed individual consideration language and updated Benefit Application format; references added; notification given 7/29/2004 with effective date 2004-10-14.
Billing/Coding updates summary through 2025–2026
The Billing/Coding section records numerous code changes through 2024–2026, reflecting additions and removals of HCPCS and CPT codes; review the policy history and coding table for the exact current code list.
Specialty panel and Medical Director reviews & oversight
The policy has undergone multiple Specialty Matched Consultant Advisory Panel reviews and Medical Director reviews across years (including 2023–2026), with specialty and medical director oversight documented in the policy history.
- Recorded reviews include Specialty Matched Consultant Advisory Panel reviews (4/2023, 4/2024, 4/2025, 4/2026) and Medical Director reviews (4/2023, 4/2024, 4/2025, 4/2026).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.